Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy
- PMID: 32282878
- PMCID: PMC7241960
- DOI: 10.1093/brain/awaa085
Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy
Abstract
Developmental and epileptic encephalopathies are a heterogeneous group of early-onset epilepsy syndromes dramatically impairing neurodevelopment. Modern genomic technologies have revealed a number of monogenic origins and opened the door to therapeutic hopes. Here we describe a new syndromic developmental and epileptic encephalopathy caused by bi-allelic loss-of-function variants in GAD1, as presented by 11 patients from six independent consanguineous families. Seizure onset occurred in the first 2 months of life in all patients. All 10 patients, from whom early disease history was available, presented with seizure onset in the first month of life, mainly consisting of epileptic spasms or myoclonic seizures. Early EEG showed suppression-burst or pattern of burst attenuation or hypsarrhythmia if only recorded in the post-neonatal period. Eight patients had joint contractures and/or pes equinovarus. Seven patients presented a cleft palate and two also had an omphalocele, reproducing the phenotype of the knockout Gad1-/- mouse model. Four patients died before 4 years of age. GAD1 encodes the glutamate decarboxylase enzyme GAD67, a critical actor of the γ-aminobutyric acid (GABA) metabolism as it catalyses the decarboxylation of glutamic acid to form GABA. Our findings evoke a novel syndrome related to GAD67 deficiency, characterized by the unique association of developmental and epileptic encephalopathies, cleft palate, joint contractures and/or omphalocele.
Keywords: GAD1; arthrogryposis; cleft palate; hypsarrhythmia; omphalocele; suppression-burst.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.
Figures
Comment in
-
Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency.Brain. 2020 Dec 5;143(11):e91. doi: 10.1093/brain/awaa289. Brain. 2020. PMID: 33146701 No abstract available.
-
Reply: Rational therapy with vigabatrin and a ketogenic diet in a patient with GAD1 deficiency.Brain. 2020 Dec 5;143(11):e92. doi: 10.1093/brain/awaa290. Brain. 2020. PMID: 33169137 Free PMC article. No abstract available.
References
-
- Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 2005; 10: 581–8. - PubMed
-
- Dirkx R Jr, Thomas A, Li L, Lernmark A, Sherwin RS, De Camilli P, et al. Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J Biol Chem 1995; 270: 2241–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
